Glioma in the 7MM: Insights, Epidemiology and Forecast to 2032 – Promising Advances in Treatment and Challenges in Access and Reimbursement –

Glioma in the 7MM: Insights, Epidemiology and Forecast to 2032 – Promising Advances in Treatment and Challenges in Access and Reimbursement –

Glioma in the 7MM: Insights, Epidemiology and Forecast to 2032 – Promising Advances in Treatment and Challenges in Access and Reimbursement –

DUBLIN–(BUSINESS WIRE)–The “Glioma – Market Insights, Epidemiology and Forecast to 2032” report has been added to’s offering.

The report offers insights into glioma’s epidemiology, current treatments, emerging therapies, market dynamics, and challenges related to treatment access and reimbursement.

Gliomas constitute the majority of malignant brain tumors, accounting for 78% as per the American Association of Neurological Surgeons (AANS). These tumors are challenging to manage, with the current standard treatments often leading to relapse in 95% of patients. The glioma market was valued at around USD 1,000 million in 2022, with expectations of growth due to increasing disease incidence and positive outcomes from developmental-stage products.

Epidemiology: Glioma’s epidemiology is discussed for the 7MM (United States, EU4 countries, UK, and Japan) from 2019 to 2032. The United States contributed the highest incident cases, with Grade IV glioma being the most prevalent. The age group 60-74 years had the highest cases in 2022. Germany accounted for the most glioma cases in the EU4, while Spain had the least.

Current Treatments: AVASTIN (bevacizumab) by Genentech and TEMODAR (temozolomide) by Merck are key therapies for glioma. AVASTIN is an angiogenesis inhibitor that blocks VEGF, and TEMODAR, an alkylating agent, is often used in GBM treatment. The report emphasizes the introduction of biosimilars like MVASI, ZIRABEV, and ALYMSYS following AVASTIN’s patent expiration.

Emerging Drugs: Several promising drugs are in development for glioma. Ofranergene obadenovec (VB-111) from VBL Therapeutics is a targeted gene-therapy agent. SurVaxM by MimiVax is an immunotherapeutic vaccine that targets survivin. Vorasidenib (AG-881) by Servier is a dual inhibitor of mIDH1/2, with potential for low-grade glioma. Tovorafenib (DAY101) by Day One Biopharmaceuticals is a selective kinase inhibitor under evaluation. These drugs present diverse mechanisms of action, including gene therapy and immunotherapy.

Drug Classes: The glioma treatment landscape features classes like VEGF inhibitors, alkylating agents, multikinase inhibitors, and IDH1 inhibitors. AVASTIN is an anti-angiogenic therapy blocking VEGF. TEMODAR, an alkylating agent, causes DNA cross-linkages. The emerging landscape includes cancer vaccines, protein kinase C beta inhibitors, and dendritic cell immunotherapy.

Market Outlook: Gliomas are classified into four grades based on malignancy. Surgical resection, chemotherapy, radiation, and other therapies are combined for treatment. The glioma market size in the US was around USD 650 million in 2022, projected to grow. Focus on high-grade glioma is evident due to patients’ longer survival in low-grade glioma. Promising therapies in the pipeline include gene therapy and immunotherapy.

Market Access and Reimbursement: Reimbursement for rare disease therapies faces challenges due to high costs and lack of policies. The US FDA has approved rare disease therapies, but access can be limited. Glioma treatment bears high economic burden for patients. Insurance coverage, government programs, and cost-effectiveness scenarios are discussed.

Key Topics Covered

1. Key Insights

2. Report Introduction

3. Executive Summary of Glioma

4. Key Events

5. Epidemiology and Market Forecast Methodology

6. Glioma Market Overview at a Glance

7. Disease Background and Overview: Gliomas

8. Treatment and management

9. Epidemiology and Patient Population of Glioma in the 7MM

10. Patient Journey

11. Key Endpoints in Glioma

12. Marketed Products

13. Emerging Drugs

14. Glioma: Seven Major Market Analysis

15. Unmet Needs

16. SWOT Analysis

17. KOL Views

18. Market Access and Reimbursement for Glioma

19. Appendix

A selection of companies mentioned in this report includes:

  • Aivita Biomedical
  • AnHeart Therapeutics
  • Bayer
  • Beigene
  • BioMimetix
  • Bristol Myers Squibb
  • Chimerix
  • CNS Pharmaceuticals
  • Day One Biopharmaceuticals
  • Denovo Biopharma
  • DNAtrix
  • Eisai and Merck Sharp & Dohme
  • Eli Lilly
  • Enterome
  • Epitopoietic Research Corporation (ERC)
  • Forma Therapeutics
  • Genenta Science
  • Hoffmann-La Roche
  • Immunomic Therapeutics
  • Imvax
  • Incyte Corporation
  • Inovio Pharmaceuticals
  • Istari Oncology
  • Karyopharm Therapeutics
  • Kazia Therapeutics
  • Kintara Therapeutics
  • Laminar Pharmaceuticals
  • Medicenna Therapeutics
  • MedImmune
  • MimiVax
  • Northwest Therapeutics
  • Oblato
  • Orbus Therapeutics
  • Servier
  • SonALAsense
  • SpringWorks Therapeutics
  • TME Pharma
  • TVAX Biomedical
  • VBI Vaccines
  • VBL Therapeutics

For more information about this report visit

About is the world’s leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.


Laura Wood, Senior Press Manager

For E.S.T Office Hours Call 1-917-300-0470

For U.S./ CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900